FDA clears hNPC01 neural cell therapy trials for hemorrhagic stroke and traumatic brain injury
FDA clears Hopstem’s hNPC01 neural cell therapy for trials in hemorrhagic stroke and traumatic brain injury, with Fast Track status in both.
Pharma & Biotech
How Bioxodes is positioning BIOX-101 for accelerated approval in intracerebral hemorrhage
Can BIOX-101 become the first disease-modifying therapy for intracerebral hemorrhage? Explore Bioxodes’ accelerated approval strategy.
Pharma & Biotech
Why Bioxodes’ adaptive trial strategy could accelerate approval timelines in stroke therapeutics
Bioxodes advances BIOX-101 into pivotal trials for intracerebral hemorrhage. Find out how this strategy could reshape stroke treatment pathways.